Urine Biomarker Detection via Microvesicle Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting prostate cancer biomarkers in urine samples require invasive procedures like digital rectal exams and sample preparation involving cellular pellet isolation, leading to lower detection rates and increased patient discomfort.
Innovation Solution
A non-invasive method that extracts nucleic acids from urine samples, detects the expression levels of PCA3, ERG, and SPDEF, normalizes their ratios, and compares them to a predetermined cutoff value to identify high-risk prostate cancer, without the need for digital rectal exams or cellular pellet isolation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If digital rectal exam or prostate massage is performed prior to urine collection, then the detection rate of prostate biomarkers improves, but patient discomfort and invasiveness increase
Solution Approach 1:
The patent extracts and analyzes microvesicles from urine samples, isolating the diagnostic information carrier from the need for invasive procedures. By focusing on microvesicles that naturally shed into urine, the method obtains prostate biomarkers without requiring digital rectal exam or prostate massage, thus resolving the contradiction between detection reliability and patient comfort
Solution Approach 2:
Microvesicles serve as an intermediary carrier that transports prostate biomarkers into urine. The patent utilizes these microvesicles as a mediator to access prostate-specific information (PCA3, ERG, SPDEF genes) through a non-invasive urine collection method, eliminating the need for direct prostate manipulation while maintaining diagnostic accuracy
2Measurement precision
If cellular pellet isolation is performed on urine samples, then biomarker detection sensitivity improves, but sample preparation complexity and time increase
Solution Approach 1:
The patent extracts nucleic acids directly from whole urine samples or simple urine filtrates, eliminating the complex cellular pellet isolation step. By using direct extraction methods from urine, the protocol reduces preparation complexity while maintaining sensitivity through optimized nucleic acid extraction and microvesicle enrichment techniques
Solution Approach 2:
The patent replaces mechanical centrifugation-based cellular pellet isolation with chemical/biochemical extraction methods. By using direct nucleic acid extraction from urine or simple filtration followed by extraction, the method substitutes complex mechanical separation with more straightforward biochemical protocols, reducing equipment requirements and preparation time
3Measurement precision
If multiple biomarkers are detected and normalized, then diagnostic accuracy improves, but assay complexity increases
Solution Approach 1:
The patent combines detection of multiple biomarkers (PCA3, ERG, SPDEF) into a single integrated assay. By simultaneously measuring these genes and applying a unified normalization approach using SPDEF as reference, the method achieves high diagnostic accuracy while maintaining assay simplicity through combined analysis rather than separate tests
Solution Approach 2:
The patent uses SPDEF as a universal reference gene that serves multiple functions: normalizing variation in nucleic acid extraction efficiency, accounting for differences in microvesicle yield, and providing an internal control for assay performance. This multi-functional reference approach simplifies the overall assay design while enabling accurate multi-biomarker detection
Data Source
Figure 1A
Figure 1B
Figure 2A~2B
AI summary
The present invention relates generally to the field of biomarker analysis, particularly determining gene expression signatures from urine samples. The disclosure provides compositions, kits and methods for diagnosing a prostate disorder such as prostate cancer in a male subject.